The completion of the merger with ImmunogenX has led to a decrease in First Wave BioPharma's stock price. This could be due to various factors such as market perception of the merger's value, dilution of shares, or concerns about the integration process. The immediate negative reaction in stock price reflects investor skepticism or caution regarding the merger's short-term benefits.